share_log

泰格医药涨6.64%,开源证券二个月前给出“买入”评级

Stock Star ·  Nov 20, 2024 08:12

今日泰格医药(300347)涨6.64%,收盘报65.2元。

2024年8月31日,开源证券研究员余汝意,汪晋发布了对泰格医药的研报《公司信息更新报告:Q2业绩环比改善,新签订单整体稳健增长》,该研报对泰格医药给出“买入”评级。研报中预计2024-2026年归母净利润为16.68/20.56/22.90亿元(原预计22.40/24.91/28.19亿元),对应EPS为1.93/2.38/2.65元,当前股价对应PE为26.4/21.4/19.2倍,考虑公司作为国内临床CRO龙头竞争力较强,维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算,该研报作者对此股的盈利预测准确度为71.14%。

证券之星数据中心计算显示,对该股盈利预测较准的分析师团队为国海证券的孔维崎。

泰格医药(300347)个股概况:

big

以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 203

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.